Feature | Thrombosis and COVID-19: FAQs For Current Practice
Publication Title
American College of Cardiology: Cardiology Magazine
Document Type
News Article
Publication Date
4-22-2020
Keywords
2019-nCoV; cards; cards publication; Anticoagulants, Heparin, Low-Molecular-Weight, Heparin, Venous Thromboembolism, Critical Illness, Fibrinolytic Agents, Fibrinogen, Patient Discharge, Superinfection, Respiration, Artificial, Netherlands, COVID-19, Coronavirus, Coronavirus Infections, International Normalized Ratio
Abstract
An FAQ on the potential impact of COVID-19 on thrombotic and/or bleeding risk from ACC's Science and Quality Committee summarize the current data on the risk, potential need for hemostasis/coagulation testing, VTE prophylaxis, and therapeutic anticoagulation in patients with COVID-19 without confirmed/suspected thrombosis.
Area of Special Interest
Cardiovascular (Heart)
Specialty/Research Institute
Cardiology
Specialty/Research Institute
Infectious Diseases
Specialty/Research Institute
Center for Cardiovascular Analytics, Research + Data Science (CARDS)
